(Q42653421)

English

Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

multicenter clinical trial

0 references

John D Hainsworth

4

object named as

John D Hainsworth

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

author name string

David R Spigel

1

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Ming Lin

2

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Vincent O'Neill

3

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

language of work or name

0 references

publication date

1 June 2008

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

112

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

2749-2755

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23490

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23490

7 January 2021

based on heuristic

inferred from DOI database lookup

New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23490

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23490

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23490

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23490

7 January 2021

based on heuristic

inferred from DOI database lookup

High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23490

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23490

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor targeting in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23490

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemoprevention of breast cancer: a model for change

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23490

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23490

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23490

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.23490

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42653421&oldid=1964622879"